Process for preparing beta 3 agonists and intermediates
The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.
1. A crystalline form of Compound I-7:
characterized by a powder X-ray diffraction (XRPD) pattern comprising °2θ peaks at about 5.5, 8.7, and 11.0.
2. The crystalline form of Compound I-7 of claim 1 , wherein the crystalline form is characterized by the XRPD pattern further comprising a °2θ peak at about 17.5.
3. The crystalline form of Compound I-7 of claim 1 , wherein the crystalline form is characterized by the XRPD pattern further comprising a °2θ peak at about 22.7.
4. The crystalline form of Compound I-7 of claim 1 , wherein the crystalline form is characterized by the XRPD pattern further comprising °2θ peaks at about 17.5 and 22.7.
5. The crystalline form of Compound I-7 of claim 1 , characterized by an XRPD pattern as shown in FIG. 2 .
6. The crystalline form of Compound I-7 of claim 1 which is anhydrous.
7. The crystalline form of Compound I-7 of claim 1 , wherein the crystalline form is characterized by an XRPD pattern comprising the following reflections with d-spacing:
Position [°2 Theta]
d-spacing [Å]
5.4897
16.09873
8.7494
10.10683
11.0426
8.01261
16.4521
5.38818
16.6518
5.32402
17.4975
5.06857
18.853
4.7071
21.2176
4.18756
21.7532
4.08564
22.7425
3.9101
8. A composition comprising the crystalline form of Compound I-7 of claim 1 .